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Abstract. Microvesicles (MVs) shed from G26/24 oligodendro-
glioma cells were previously reported to cause a reproducible, 
dose-dependent, inhibitory effect on neurite outgrowth, and 
eventually neuronal apoptosis, when added to primary cultures 
of rat cortical neurons. These effects were reduced but not 
abolished by functional monoclonal antibodies against Fas-L. 
In order to investigate whether MVs contain other factors able 
to induce cell death, we tested them for TRAIL and found clear 
evidence of its presence in the vesicles. This finding suggests the 
possibility that Fas-L and TRAIL cooperate in inducing brain 
cell death. Aimed at understanding the route through which the 
vesicles deliver their messages to the target cells, we labeled 
oligodendroglioma cells with radioactive methionine and then 
added the labeled vesicles shed from tumor cells to unlabeled 
astrocytes in culture. Here we report that labeled proteins were 
delivered to the test cells. In order to investigate whether astro-
cytes, like neurons, are sensitive to oligodendroglioma-derived 
vesicles, MVs were prepared from media conditioned by G26/24 
oligodendroglioma cells and added to primary cultures of rat 
cortical astrocytes. These cells were clearly more resistant than 
neurons to microvesicle-induced damage: a high dose (40 µg) of 
shed MVs induced cell death in only about 40% of astrocytes. 
Finally, we demonstrated that Hsp70 is specifically enriched 
in MVs which also contain, even if at lower level, the Hsc70 
constitutive chaperone.
Introduction
A peculiar route for cell-to-cell communication could be medi-
ated by extracellular membrane vesicles. Two distinct types of 
signaling vesicles have been identified up to now: i) vesicles with 
a diameter of 30-100 nm, known as exosomes, released from 
the cell by exocytosis of multivesicular bodies (MVBs), intra-
cellular organelles of the endosomal system; ii) small vesicles, 
called shed vesicles (SVs), 100 nm - 1 µm in diameter, released 
into the extracellular space by direct budding from the plasma 
membrane. Mixed vesicle populations, containing both shed-
ding vesicles and exosomes, will be referred to as microvesicles 
(MVs) (1,2).
Upon release, both types of microvesicles circulate in the 
extracellular space adjacent to the site of discharge where they 
can be broken down, often within a few minutes. Some of 
them, however, can move some distance by diffusion and can 
appear in biological fluids, such as cerebrospinal fluid, blood 
and urine. In some cases microvesicles deliver transmembrane 
signals which activate surface receptors (3); in other cases they 
function not only as messengers, but also as platforms necessary 
for the coordinate development of multisignaling processes (4). 
Being membrane-bound structures, microvesicles can fuse with 
their target cells. Because of these properties, MVs, which seem 
to be enriched in specific proteins and mRNAs (5), have been 
suggested to function in signaling as well as in the horizontal 
transfer of their membrane and/or cargo molecules (6).
Different neural cells release MVs into the extracellular 
space. Neurons and astrocytes shed extracellular vesicles which 
contain FGF2 and VEGF and could be involved in interaction 
with endothelial cells, to form the blood-brain barrier (7,8). 
Also brain tumor cells release MVs in the extracellular space. 
Glioblastomas release exosomes containing mRNA, miRNA 
and angiogenic proteins (9).
Previous studies on oligodendroglioma cell cultures revealed 
that these cells shed MVs which inhibited neurite sprouting and 
caused apoptosis to primary fetal rat neurons, after 48-72 h of 
incubation (10). Proapoptotic effects of vesicles on neurons were 
dose-dependent and were induced also when concentrations of 
tumor-derived vesicles were similar to those probably occurring 
in vivo, when an oligodendroglioma tumor is growing inside the 
central nervous system (CNS).
These vesicles contain Fas-L, a molecule that has been iden-
tified also in vesicles shed by other kinds of tumor cells (11,12), 
while, on the other hand, Fas receptor has been reported to be 
expressed both in neurons and astrocytes (13). The presence of 
Fas-L in vesicles shed by tumor cells is generally considered as 
part of the mechanism by which tumors acquire the capability 
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to escape from host immune surveillance. The presence of the 
molecule in vesicles shed by oligodendroglioma cells appears to 
have an additional meaning in allowing production of a cell-free 
environment in which tumor cells can grow. Interestingly, func-
tional monoclonal antibodies against Fas-L were able to reduce 
but not to abolish the inhibitory effects of vesicles on neurite 
growth and their proapoptotic effects on neurons. In looking for 
additional factors involved in cell death, in the present study we 
investigated the possible presence of TRAIL in MVs. We also 
analyzed loading of MVs with molecular chaperones. Finally, 
we studied the effects of G26/24-shed MVs on astrocytes.
Materials and methods
Animals. Procedures involving animals were conducted accor-
ding to the European Community Council Directive 86/609, 
OJL 358 1, December 12, 1987. Winstar rats (Stefano Morini, 
San Polo d'Enza, Italy) were housed in the institutional animal 
care facility of Dipartimento di Scienze e Tecnologie Molecolari 
e Biomolecolari (STEMBIO), University of Palermo, Palermo, 
Italy, under the direction of a licensed veterinarian who approved 
the protocols.
Cell culture. Astrocytes were purified from brain cortices of 
2-day-old rats, as described by Cole and De Vellis (14), exploiting 
the differences in adhesion of the various cell types.
G26/24 oligodendroglioma cells and primary astrocytes 
were cultured in DME-Ham's F-12 (2:1) medium supplemented 
with 10% fetal calf serum (FCS), and 100,000 U penicillin, 
100 mg streptomycin and 250 µg amphotericin B per liter. Cell 
cultures were maintained in humidified 5% CO2/95% air, at 
37˚C.
Preparation of microvesicles from the cell culture medium. 
Vesicles were prepared from oligodendroglioma G26/24 subcon-
fluent healthy cells grown in FCS-free medium, as previously 
described (15). After 24 h of culture, conditioned media were 
centrifuged at 2,000 x g for 15 min and then at 4,000 x g for 
15 min. The supernatant was centrifuged at 105,000 x g (Ti60 
Rotor, Beckman) for 90 min at 4˚C. Pelleted vesicles were 
suspended with phosphate-buffered saline, pH 7.5 (PBS) and 
the amount of isolated vesicles was determined by measuring 
protein concentration by the Bradford microassay method (Bio-
Rad) using bovine serum albumin (Sigma-Aldrich) as a standard.
Cell lysate preparation. Cultured cells were washed in PBS, 
scraped from the wells, and centrifuged at 600 x g for 5 min. 
The pellet was homogenized in homogenization buffer (0.32 M 
sucrose; 50 mM sodium phosphate buffer, pH 6.5; 50 mM KCl; 
0.5 mM spermine; 0.15 mM spermidine; 2 mM EDTA; and 
0.15 mM EGTA), containing the protease inhibitors aprotinin 
(2 µg/ml), antipain (2 µg/ml), leupeptin (2 µg/ml), pepstatin A 
(2 µg/ml), benzamidine (1.0 mM), and phenylmethylsulfonyl 
fluoride (PMSF) (1.0 mM), all from Sigma-Aldrich (MO, USA).
Western blot analyses. After electrophoresis (SDS-PAGE), 
total proteins were immunoblotted onto a PVDF (Poly-
vinylidene fluoride) membrane (Immobilon P, Millipore, MA, 
USA). The gel was equilibrated with CAPS 1X (100 mM 
N-cyclohexyl-3-aminopropanesulfonic acid, pH 11.0 + 10% 
methanol). The PVDF membrane was activated by wetting in 
methanol 100% for 30 sec, and then equilibrated with CAPS 
1X for 30 sec. The immunoblot was done in the Trans-Blot® 
Bior-Rad for 45 min at 170 mA. After blotting, the membrane, 
that contains the proteins, was saturated with 3% BSA, 10% 
FCS, PBS 1X for 1 h, and then incubated overnight with one of 
the following antibodies: anti-TRAIL, anti-Hsp70, anti-Hsp90, 
anti-Hsc70. The antibodies are in 3% BSA, 1X PBS.
After washing with PBS containing 0.1% Tween-20, the 
membranes were incubated for 1 h with alkaline phosphatase-
conjugated secondary antibodies. Immunocomplexes were 
visualized by adding the substrates of alkaline phosphatase, 
NBT and BCIP (Sigma-Aldrich).
Treatments of astrocytes with vesicles and vitality assay. Effects 
of vesicles shed from G26/24 cells into the medium were analyzed 
by adding to primary cultures of astrocytes an aliquot of MVs 
containing 10-40 µg of proteins. The effects were analyzed after 
48 h of culture by vitality assay: cells were stained with a combi-
nation of the fluorescent DNA-binding dyes, acridine orange 
(AO) and ethidium bromide (EB), 100 µg/ml in PBS for each 
dye (AO/EB colorimetric assay). The differential uptake of these 
two dyes allowed identification of viable and non-viable cells by 
fluorescence microscopy: normal nuclei in alive cells appeared 
bright green; apoptotic nuclei in dead cells appeared bright 
orange with highly condensed chromatin. Statistical analysis of 
the results was done by counting green and orange/red cells in 
different fields. Numbers obtained from different experiments 
were used to calculate average percentages of viable and dead 
cells, as well as standard deviations.
Metabolic labeling of G26/24 cells and astrocytes with 35S- 
methionine. G26/24 cells and astrocytes were incubated for 
12 h in a methionine-free medium, to make them proner to 
methionine uptake afterward. Then cells were grown in methi-
onine-free medium, to which 4 µCi of 35S-methionine were 
added/ml of medium, and cultured for 16 h. During this period, 
they started producing labeled proteins. Cells were washed 
once with PBS and then cultured for 24 h in NIH serum-free 
medium. Medium conditioned by G26/24 cells was finally 
collected and centrifuged to obtain labeled vesicles. When the 
last conditioned medium was collected, cells were also lysed to 
obtain total labeled cell proteins. From astrocytes, total labeled 
cell lysates were prepared directly. Total cell lysates as well as 
G26/24-derived MV proteins were analyzed by SDS-PAGE 
and fluorography.
Treatments of astrocytes with 35S-labeled vesicles. Primary 
cultures of astrocytes were incubated for 24 h with 35S-labeled 
vesicles from G26/24 cells, and then washed with PBS. Cells 
were lysed to obtain total cell proteins. Total proteins from 
control labeled astrocytes, from astrocytes pre-incubated with 
labeled MVs shed by G26/24 cells, and from labeled MVs 
were analyzed by SDS-PAGE and fluorography.
Results
Extracellular vesicles interact with target cells. To clarify the 
fate of MVs after shedding into the extracellular space and their 
interaction with target cells, G26/24 cells and primary astro-
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cytes were metabolically labeled with 35S-methionine. If labeled 
proteins entered MVs, they could be used to trace the destiny 
of MV components after release from G26/24 cells. From both 
labeled G26/24 cells (Fig. 1, lane 1: Lys) and astrocytes (Fig. 1, 
lane 4: L) total cell lysates were also prepared, in order to have 
reference patterns of total labeled proteins from the two cell 
types. In order to study their fate, labeled MVs (Fig. 1, lane 2: 
MVs) were added to unlabeled astrocytes (Fig. 1, lane 3: U). In 
detail, astrocytes were incubated for 24 h with MVs containing 
10-40 µg of proteins, and then washed with PBS containing an 
excess of unlabeled methionine to eliminate traces of labeled 
material before homogenizing the cells. SDS-PAGE analysis of 
lysates, followed by fluorography of the gel revealed the pres-
ence of labeled bands in unlabeled astrocytes (Fig. 1, lane 3: U), 
suggesting transfer of labeled proteins, probably through fusion 
of MVs with the plasma membrane of unlabeled target cells.
Extracellular vesicles shed from G26/24 cells contain TRAIL 
and induce astrocyte damage. Oligodendroglioma G26/24 
cells are already known to release into the culture medium 
MVs, which are able to induce cell death in primary neurons 
(10). Investigation of the composition of MVs had already 
evidenced the presence of Fas-L, a proapoptotic factor. 
However, inhibition of Fas-L activity reduced but not elimi-
nated the apoptotic effects on neurons. Thus, we investigated 
possible presence of other factors, besides Fas-L, in MVs. A 
likely candidate seemed tumor necrosis factor-related apop-
tosis-inducing ligand (TRAIL), a protein with well known 
pro-apoptotic activity (16,17). We found that TRAIL is visible 
both in microvesicles (lane 1) and total cell lysates (lane 2) 
from G26/24 oligodendroglioma cells (Fig. 2).
The effects of purified MVs were directly tested on 
astrocytes. Astrocytes were treated for 48 h with aliquots of 
MVs containing 10-40 µg of proteins, and cell vitality was 
assayed by acridine orange and ethidium bromide staining. 
Astrocytes were quite resistant to the lowest doses of vesicles 
(not shown). When treated with 40 µg of proteins, however, 
cell death was induced on average by ~25% of astrocytes (the 
maximum value observed was ~50%). These data suggest that 
oligodendroglioma-shed vesicles have cell death-inducing 
effects also on astrocytes, but that these cells are more resistant 
than neurons (10) to their effects (Fig. 3).
Figure 1. SDS-PAGE and fluorography of G26/24 total lysates (lane 1, Lys) and 
shed microvesicles (lane 2, MVs) as well as of unlabeled astrocytes (lane 3, U) 
incubated with 35S-labeled vesicles shed from G26/24 cells. Total cell lysates 
from labeled astrocytes were also analyzed as a control (lane 4, L).
Figure 2. Microvesicles contain TRAIL. Western blot analysis of microvesicles 
(lane 1) and total lysates from G26/24 cells (lane 2). Proteins were immuno-
stained with an anti-TRAIL antibody.
Figure 3. Effects of vesicles shed from G26/24 cells on primary cultures of astrocytes. Vitality assays with AO/EB: (a), control astrocytes; (b), astrocytes incu-
bated with MVs from G26/24 cells for 48 h. Statistical analyses are shown in graphic form in the lower part of the figure: (c), control astrocytes; (d), astrocytes 
incubated with MVs. The grey bars represent means of 4 different experiments. Standard deviations are also shown (black bars). The difference between the 
means were highly significant (p<0.005).
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Oligodendroglioma G26/24 cells release Hsp70 and Hsc 70 
in the extracellular culture medium. MVs shed from G26/24 
cells were finally tested by Western blotting for the presence 
of molecular chaperones. The results of these assays showed 
that Hsp70 chaperone is highly enriched in MVs respect to the 
whole cell lysate, where it is not visible at all (Fig. 4).
As a control we also studied distribution of Hsc70 and 
Hsp90. The first protein is present both in MVs and in the total 
cell lysate, whereas Hsp90 is only visible in the cell lysate, at 
a very low level.
Discussion
Oligodendrogliomas are slowly growing tumors which however 
cause brain damage. This effect has been primarily attributed to 
compression on surrounding brain cells, caused by the increasing 
size of the tumor. More recently, it was suggested that G26/24 
oligodendroglioma cells can actively induce neuronal damage by 
releasing molecules able to inhibit neurite sprouting and to even-
tually cause neuronal death (10). Interestingly, such molecules 
seem to be released through an unusual route involving shedding 
of extracellular membrane microvesicles (10).
MVs originate from the plasma membrane through a 
mechanism which resembles budding of viruses from infected 
cells and requires production of RNA and proteins. Although 
tumor cells are particularly active in shedding MVs, it has been 
reported that vesicles are also released from non-tumor cells 
(7,8,18,19). On the other hand, it remains not completely under-
stood how microvesicles deliver their cargoes and whether or 
not they fuse with their target cells. Our results confirmed the 
hypothesis that at least part of the vesicle population released 
from oligodendroglioma cells fuse with surrounding cells. 
Labeled proteins were indeed found in lysates from unlabeled 
astrocytes incubated with labeled microvesicles shed by G26/24 
cells.
Previous analyses demonstrated that extracellular micro-
vesicles (MVs) released from G26/24 cells contain Fas-L, a well 
known pro-apoptotic agent (10). Moreover, functional mono-
clonal antibodies against Fas-L were able to counteract at least 
in part the pro-apoptotic effect of MVs (10).
The fact that the counteracting effect of anti-Fas-L anti-
bodies was only partial suggested that other cell death-inducing 
molecules are present in MVs. In looking for other pro-apoptotic 
proteins present in the microvesicles, we tested the vesicle 
fraction for TRAIL and found clear evidence of its presence in 
MVs. This finding suggested a possible involvement of TRAIL, 
in synergy with Fas-L, in the pro-apoptotic effects of vesicles 
on brain cells.
To understand the role of MVs in apoptosis and their 
possible interaction with different brain cell types, we inves-
tigated their effects on primary astrocytes, which have been 
reported to be resistant to different stresses which are more 
effective on neurons. As shown in the present study, 25-50% of 
astrocytes were damaged when incubated with 40 µg of shed 
MVs. However, they were almost unaffected (data not shown) 
when treated with lower doses of vesicles, already able to kill 
neurons (10).
Heat shock protein 70 (Hsp70) is a chaperone known to 
be involved in the formation of both intracellular and extra-
cellular vesicular structures, such as those related to viral 
budding. Specialized membrane microdomains, known as 
lipid rafts, may play a role in Hsp70 exocytosis (20), inducing 
the release of the protein in the extracellular space in response 
to cellular stress. Moreover, Hsp70 seemed to be involved in an 
exosome-dependent trafficking (21). It has been also suggested 
that extracellular Hsp70 may act as a potent danger signal to 
the immune system (22). Here we demonstrated that Hsp70 is 
specifically enriched in the microvesicles which also contain, 
even if at much lower level, the Hsc70 constitutive chaperone. 
On the other hand, we did not find evidence for the presence in 
MVs of the Hsp90 chaperone.
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